Sat, Mar 28, 2020 page3

• Virus Outbreak: Locally grown tea may have treatment key, study says

  • Staff writer, with CNA
  • • 
    • 
    • 

  Researchers have identified an antioxidant in locally grown black tea leaves as a potential inhibitor of protease activity in SARS-CoV-2, the virus that causes COVID-19, Chiayi Chang Gung Memorial Hospital said on Wednesday.

  A research team led by Wu Ching-yuan (吳清源), head of the hospital’s Department of Traditional Chinese Medicine, used a computer program to identify potential antiviral components in traditional plants, the hospital said in a statement.

  Theaflavin, a polyphenolic compound, shows broad-spectrum antiviral activity against several viruses and could be used as a lead compound for the development of a SARS-CoV-2 inhibitor to target the DNA-directed ribonucleic acid (RNA) polymerase (RdRp) enzyme.

  

  Chiayi Chang Gung Memorial Hospital’s Wu Ching-yuan, third right, head of the traditional Chinese medicine department, Lin Yu-shih, second right, head of the pharmacy department, and Lung Jr-hau, right, head researcher at the research and development department, gesture with other researchers in a lab in Chiayi County on Tuesday.

  Photo copied by Lin I-chang, Taipei Times

  In coronaviruses, RdRp catalyzes the replication of RNA from a template, making it an attractive candidate to help develop a treatment, Wu said.

  RdRp in SARS-CoV-2 is also a primary target for the antiviral remdesivir, which the WHO has called the most promising drug available for the treatment of COVID-19, he said.

  Remdesivir works by inhibiting RdRp, which many RNA viruses — including coronaviruses — use to replicate themselves.

  The antiviral effects of theaflavin are similar to those of remdesivir, Wu said.

  However, the exact in vivo effect is still unclear, and further research is needed to confirm the mechanism whereby theaflavin targets SARS-CoV-2, Wu said.

  The findings were published by the American Society for Microbiology in the Journal of Medical Virology on March 13, the hospital said.

  In other news, the Central Epidemic Command Center (CECC) on Thursday said that quinoline antimalarial drugs, which have been discussed as a possible treatment for COVID-19, are produced in Taiwan and could be made available if testing proves them to be effective against the novel coronavirus.

  In a small French study, doctors used a drug in the quinoline family — hydroxychloroquine — to reduce the duration and severity of COVID-19 symptoms in people with mild cases, said Chang Shan-chwen (張上淳), convener of the center’s expert advisory panel.

  If properly tested and approved, a process that normally takes 12 to 18 months, the drug could conceivably reduce the burden on medical resources such as quarantine facilities, Chang said.

  Minister of Health and Welfare Chen Shih-chung (陳時中), who heads the CECC, said that there is one manufacturer of quinoline drugs in Taiwan.

  If the treatment were proved to be viable, the government’s first priority would be to guarantee domestic supply, Chen said.

  The government could participate in the distribution of the drug on the precondition of not harming the manufacturer’s commercial interests, Chen said.

  Internationally, drug distribution rights could be used diplomatically to build ties with international partners to address shortages amid the pandemic, he said.

  Drugs that have been touted as potentially effective against COVID-19 have become the subject of heated competition in the past few weeks as governments scramble to combat the disease.

  Remdesivir is being used on a trial basis in Taiwan and has reduced fevers in the three COVID-19 patients who have been treated with it, although its effect on overall recovery time is still being studied, Chang said.
• Most Popular

  • 1

    Taobao fined over ads, risks losing license: ministry

  • 2

    Taiwan, Tuvalu sign agreements on labor cooperation

  • 3

    Bukele proposes prisoner swap with Maduro

  • 4

    HK, Macau residency rules tightened

  • 5

    Mexican baseball’s growth starting to rival soccer clubs